JPMorgan Chase has introduced credit default swaps for major tech firms as geopolitical tensions and AI-fueled borrowing raise recession concerns reminiscent of 2008.
Nobel Prize-winning economist Paul Krugman has raised serious concerns about alleged insider trading involving $580 million in oil and S&P futures positions executed minutes before major geopolitical announcements, questioning national security protocols.
Independent analyst Anand Tandon outlines a selective approach to Indian equities, identifying private banking as a prime opportunity while recommending caution on IT and platform stocks amid geopolitical headwinds.
Invesco analysts suggest the recent US dollar strength fueled by Middle East tensions is temporary, with fundamental overvaluation concerns and export worries likely to weigh on the currency long-term.
Indian stock exchanges NSE and BSE will observe a trading holiday on March 26, 2026, in observance of Shri Ram Navami. Traders and investors should plan their transactions accordingly.
Kotak Mahindra Bank has initiated a reconciliation process for ₹150 crore in fixed deposits tied to Panchkula Municipal Corporation following reports of missing funds. The bank has filed a police complaint while maintaining compliance with banking protocols.
Easing crude oil prices and improving global sentiment have sparked renewed interest in select mid-cap stocks. Analysts identify high-conviction buy opportunities with significant upside potential.
United Spirits [UNITEDSPIRIT] divests its Royal Challengers Bangalore stake for ₹16,660 crore, with brokerages citing significant value creation potential and improved capital allocation prospects for the spirits manufacturer.
Bernstein cautions that escalating tensions in Iran could weaken the Indian rupee beyond 98 per USD and pressure the Nifty 50 index, citing vulnerability to energy price shocks.
The Indian stock market will remain closed on March 26, 2026, for Mahavir Jayanti, marking the first of three consecutive holidays in the upcoming trading week.
The record-breaking Royal Challengers Bangalore acquisition has triggered a significant re-rating across IPL-linked stocks, with Sun TV Network and RPSG Ventures emerging as the biggest gainers.
Five Nifty500 stocks surged above their Volume Weighted Average Price on March 24, signaling potential bullish momentum. BLS International Services [BLSINTERNATIONAL] led the charge with gains exceeding 2% above VWAP levels.
Market regulator Sebi has greenlit the use of WhatsApp for buy and sell instructions from investors to brokers, but with stringent record-keeping and audit trail requirements to prevent trading malpractices.
Analysts identify a curated list of 10 banking stocks offering significant upside potential of up to 26% within a 12-month timeframe, presenting opportunities for long-term investors amid market volatility.
U.S. business activity contracted significantly in March, hitting an 11-month low as geopolitical tensions in the Middle East drive up energy and input costs, threatening to accelerate inflation globally.
Benjamin Disraeli's wisdom on skepticism versus conviction reveals why successful investors act decisively when others hesitate. Learn how discipline and courage separate wealth creators from market fence-sitters.
A new CBRE-FICCI report reveals that 65% of Indian office occupiers plan to integrate flexible workspaces into their portfolios by 2027, signaling a major transformation in corporate real estate demand.
The Securities and Exchange Board of India introduces stricter conflict-of-interest regulations for its leadership, aiming to enhance transparency and accountability in India's financial markets.
VRB Consumer Products, the manufacturer behind the popular Veeba sauce and condiments brand, is gearing up for a public market debut with ambitions to raise approximately $200 million through fresh equity issuance.
Amir Chand Jagdish Kumar's IPO shows a ₹7 grey market premium on day 1. Explore GMP trends, subscription metrics, and key considerations before investing in this public offering.
India's GLP-1 medication market is poised for explosive growth, with the market expected to reach ₹12,000 crore within five years as generic semaglutide launches drive accessibility and competition among pharmaceutical companies.